PFAS Compliance is the practice of identifying, controlling, and where necessary eliminating per- and polyfluoroalkyl substances (PFAS) across medical device materials, components, and manufacturing processes to meet regulations including EU REACH, US state PFAS statutes, and disclosure laws such as California Proposition 65, without compromising device performance or biocompatibility.
What is PFAS Compliance?
PFAS are a family of thousands of synthetic, fluorinated chemicals valued for chemical resistance, low friction, and thermal stability. In medical devices, PFAS most often show up as fluoropolymers: PTFE (polytetrafluoroethylene) linings on catheters and guidewires, FEP and PVDF in tubing and cable insulation, and PTFE-based gaskets and coatings on implants. Because most PFAS resist environmental breakdown, regulators call them “forever chemicals” and are narrowing where they can still be used.
For a device OEM or CDMO, PFAS compliance spans materials engineering, supply chain management, and regulatory affairs at once. It starts at material selection, continues through supplier qualification and bill-of-materials review, and ends in the technical documentation filed with regulators and customers. Unlike a fixed biocompatibility test, it keeps moving, since several major rules are still being finalized.
Why PFAS Compliance matters in medical device development
Getting PFAS compliance wrong rarely shows up as a single dramatic failure. It shows up as a slow-building risk. A supplier’s PTFE resin gets flagged under a new state reporting law, and the program has a fixed window to document its use. A component that was fine at design freeze becomes restricted before the device reaches full commercial volume, forcing a material substitution, biocompatibility retesting, and a design change control cycle late in the product’s life. Large OEMs now ask CDMOs and suppliers for PFAS declarations as a condition of vendor qualification, so a weak answer can cost a contract before a regulator ever gets involved.
On the disclosure side, states including Minnesota and Maine require manufacturers to report intentionally added PFAS in products sold within their borders, and California’s Proposition 65 requires warnings for products containing certain listed PFAS. None of this is hypothetical. It is active reporting and disclosure work with real deadlines, running in parallel with the EU’s own proposed restriction.
How PFAS Compliance works
A working PFAS compliance program has a few recurring parts, whether it sits inside QARA, materials engineering, or both.
- Material and supply chain mapping: a full bill-of-materials review that goes past the primary material spec, since PFAS often enter through a supplier’s secondary process, such as mold release agents, gaskets, or adhesives, rather than the resin itself.
- Regulatory tracking: watching the EU REACH Substances of Very High Concern (SVHC) candidate list, the proposed EU-wide PFAS restriction moving through ECHA’s Committee for Risk Assessment (RAC) and Committee for Socio-Economic Analysis (SEAC), and US state statutes such as Minnesota’s Amara’s Law and Maine’s PFAS reporting rule.
- Supplier declarations and testing: collecting PFAS content declarations from material and component suppliers, and commissioning analytical testing, such as total organic fluorine screening, where a declaration is missing or unreliable.
- Risk-based substitution planning: weighing non-fluorinated alternatives against a design’s functional requirements, its biocompatibility profile under ISO 10993, and its risk file under ISO 14971, since not every fluoropolymer application has a proven substitute.
- Documentation and disclosure: keeping PFAS content data in the device master record and technical file, and preparing REACH Article 33 communications or state-mandated product reports where applicable.
- Change control: routing any material substitution through formal design change control, because swapping a fluoropolymer can affect sterilization compatibility, mechanical performance, or shelf life.
Medical devices are treated differently from consumer products in most current and proposed rules. The FDA reviewed the safety of fluoropolymer PFAS such as PTFE in 2025 and found no basis to restrict their continued use in devices, citing decades of clinical use and a joint review with ECRI. Minnesota’s and Maine’s PFAS statutes both carve out FDA-regulated medical devices from their use prohibitions, even as they extend reporting duties to other product categories. The EU’s proposed REACH restriction lists medical devices among the sectors under evaluation and is expected to include time-limited derogations, though the exact scope of those derogations is still being negotiated inside ECHA’s review process.
Common challenges and best practices
Supply chain opacity is the most common starting problem. Most OEMs don’t know which components contain PFAS because resin and coating suppliers sit several tiers away and rarely disclose fluoropolymer content unless asked directly and specifically. A related mistake is treating PFAS as one substance: it is a class of thousands of compounds with different regulatory status, and a supplier survey that just asks “do you use PFAS” tends to come back incomplete or vague.
Timing causes the rest of the trouble. Teams often discover PFAS content during a customer audit or a regulatory filing, after the design is frozen, which turns a documentation task into a redesign. Some also assume a medical device exemption is permanent. It usually isn’t. Regulatory committees reviewing the EU’s proposed restriction have already recommended narrowing some of the derogations included in the original filing.
Good programs screen for PFAS at material selection, before design freeze, not after. They ask suppliers for full material disclosure rather than a yes-or-no PFAS question, keep a living register of fluoropolymer-containing components tied to the device history file, and review regulatory trackers on a fixed schedule instead of reactively. Regulatory affairs gets pulled into material selection conversations early, alongside engineering, instead of joining after the bill of materials is locked.
How SJML helps with PFAS Compliance
SJML’s regulatory affairs team addresses PFAS and other materials of concern, alongside RoHS, REACH/SVHC, California Proposition 65, and extended producer responsibility (EPR) obligations, as part of its Compliance-as-a-Service offering. This work is coordinated with material selection and bill-of-materials review during design and engineering, so PFAS exposure gets flagged early rather than discovered late in a program. SJML’s QARA and engineering teams support supplier qualification, technical file documentation, and ongoing tracking of PFAS rules across the markets a device ships into, for new designs and for devices already in production.
Frequently asked questions
PFAS stands for per- and polyfluoroalkyl substances, a group of thousands of synthetic chemicals valued for resistance to heat, water, and chemicals. In medical devices, PFAS most commonly appear as fluoropolymers, PTFE, FEP, and PVDF, used in catheter coatings, tubing, gaskets, and cable insulation. Regulators group these compounds together mainly because of their shared environmental persistence.
No. The FDA reviewed fluoropolymer PFAS such as PTFE in 2025 and found no basis to restrict their continued use in devices. State laws in Minnesota and Maine specifically exempt FDA-regulated medical devices from their PFAS use prohibitions. The EU’s proposed REACH restriction is expected to include time-limited derogations for some medical applications, though the exact scope remains under review.
Key drivers include the EU REACH Regulation (EC) No 1907/2006 and its Substances of Very High Concern (SVHC) candidate list, the proposed EU-wide PFAS restriction under REACH Annex XVII, and US state statutes including Minnesota’s Amara’s Law and Maine’s PFAS in products law, alongside California’s Proposition 65 disclosure requirements. Coverage and exemptions vary by jurisdiction and by material.
Start with a full bill-of-materials and supplier declaration review, since PFAS often enter through secondary sources, such as mold release agents, coatings, or gaskets, rather than the primary material specification. Where supplier declarations are unclear or unavailable, targeted analytical testing, such as total organic fluorine screening, can confirm presence and estimate PFAS content.
The manufacturer typically needs to qualify an alternative material or document an applicable exemption, either of which can trigger design change control, biocompatibility retesting under ISO 10993, and updates to the technical file. Planning a substitution pathway before a restriction takes effect reduces the risk of a compliance-driven supply disruption.
Related terms
- Materials of Concern
- REACH SVHC Declaration
- Biocompatibility Testing (ISO 10993)
- Design Change Control
- Supplier Qualification
